The spin-off of its hemophilia business into a separate entity, Bioverativ (NASDAQ: BIVV), went without a hitch -- and Bioverativ's stock has racked up nice gains so far in 2017. Celgene (NASDAQ: CELG), meanwhile, saw Argus …
Investor
Celgene (CELG) stock dipped to a four-month low Monday on Wall Street disappointment that its potential blockbuster drug, ozanimod, failed to delay the …
The Market
Quadrant Capital Management LLC now owns 52,796 shares of the retailer's …
Comps, Drôme
The biotech sector has been lagging behind the major market indices, and I am finding it difficult to remember a major market advance in the NASDAQ when this sector did not lag. I have been watching this sector with a keen eye for …
NASDAQ
... (CELG) The stock of Bird Construction Inc (TSE:BDT) has "Sector Perform" rating given on Monday, May 30 by National Bank Canada. Addenda Capital Inc …
Donald Trump
If there was ever a doubt, the latest price action in Celgene Corporation (NASDAQ:CELG) should help ease those fears and usher in more investor cheer in the coming weeks. For investors sharing that vision, a CELG bull call spread can …
Celgene
The stock's average target of $13.25 is 27.77% above today's ($10.37) share price. The stock of Celgene Corporation (NASDAQ:CELG) earned "Outperform" rating by Credit Suisse on Wednesday, January 20. MSI has been the topic of a …
Investment management
On Tuesday, May 23, 2017, Celgene's shares climbed 1.38%, finishing the day at $117.31. A total volume of 4.40 …
Trial
I think it's a good stock. There was a takeover rumor today. Do not buy it for a …
CNBC13d
Jim Cramer